EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study

Christoph Theyer, Vincent Beliveau iD, Florian Krismer iD, Marina Peball iD, Katherina Mair, Beatrice Heim iD, Atbin Djamshidian, Stefan Kiechl, Wilhelm Eisner, Sabine Eschlböck, Gregor K Wenning, Peter Willeit und 3 weitere

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.14065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Christoph Theyer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. Hauptthemen laut MEDLINE: Parkinson Disease, Deep Brain Stimulation, Subthalamic Nucleus, Antiparkinson Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subthalamic deep brain stimulation (STN‐DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking.

Objective

To compare longitudinal trajectories of antiparkinsonian medication in STN‐DBS treated patients to non‐surgically treated control patients.

Methods

We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex‐distribution, and comorbidities.

Results

In 74 DBS patients levodopa‐equivalent daily dose (LEDD) were reduced by 33.9–56.0% in relation to the preoperative baseline over the 14‐year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug‐classes was observed for dopamine agonists.

Conclusion

In PD patients, chronic STN‐DBS was associated with a lower LEDD compared with control patients over 14 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDeep Brain StimulationSubthalamic NucleusAntiparkinson AgentsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesLevodopaLongitudinal StudiesTreatment Outcome

Stichwörter der Autor:innen

deep brain stimulation (DBS)levodopa equivalent daily dose (LEDD)medicationnucleus subthalamicus (STN)

Substanzen

Antiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
  • Department of Neurosurgery, Innsbruck Medical University, Innsbruck, Austria.
  • Department of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

ORCID-Profile: Vincent Beliveau, Florian Krismer, Marina Peball, Beatrice Heim, Philipp Mahlknecht

Zitieren

APA

Theyer, C., Beliveau, V., Krismer, F., Peball, M., Mair, K., Heim, B., Djamshidian, A., Kiechl, S., Eisner, W., Eschlböck, S., Wenning, G. K., Willeit, P., Seppi, K., Poewe, W., & Mahlknecht, P. (2024). Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14065

Vancouver

Theyer C, Beliveau V, Krismer F, Peball M, Mair K, Heim B, et al. Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14065

BibTeX
@article{Theyer2024,
  author = {Theyer, Christoph and Beliveau, Vincent and Krismer, Florian and Peball, Marina and Mair, Katherina and Heim, Beatrice and Djamshidian, Atbin and Kiechl, Stefan and Eisner, Wilhelm and Eschlböck, Sabine and Wenning, Gregor K and Willeit, Peter and Seppi, Klaus and Poewe, Werner and Mahlknecht, Philipp},
  title = {Long‐Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.14065}
}
Kostenlos starten →